ANALYSTS UPGRADE WITH $28 TAGRGETH.C. Wainwright analystChen startedwith a Buy rating and $28 price target. The company possesses an "intriguing" technology platform, DNAbilize, consisting of a novel and proprietary way to achieve sustainable systemic delivery of antisense oligonucleotides, Chen tells investors in a research note. Further, the analyst believes prexigebersen could have broad applicability within hematological malignancies as well as solid tumors. Source The flyCOMPANY PROFILEis a biotechnology company, which engages in the development of therapies for acute myeloid leukemia () and chronic myeloid leukemia (). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris,Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire,